Integrin Beta 7 (ITGB7) Market Size, Definition, Treatment,
Symptoms, Causes, Pipeline Review, H1 2016: Radiant Insights
Summary
Global Markets Direct's, 'Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016',
provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline
therapeutics.
The report provides comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or
ITGB7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action
(MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Receptor Beta
Subunit or ITGB7) targeted therapeutics development and features dormant and discontinued projects.
Click For Report Details @ http://www.radiantinsights.com/research/integrin-beta-7-gut-homing-receptor-betasubunit-or-itgb7-pipeline-review-h1-2016
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor
Beta Subunit or ITGB7)
- The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under
development by companies and universities/research institutes based on information derived from company and
industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till
discovery and undisclosed stages